再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新

Core Viewpoint - The company Zai Lab (09688) announced that its partner Amgen will halt the FORTITUDE-102 clinical trial due to insufficient efficacy observed in a preliminary analysis mandated by the data monitoring committee [1] Group 1 - The FORTITUDE-102 trial was assessing the combination of bemarituzumab with chemotherapy and nivolumab for first-line gastric cancer treatment [1] - The announcement was made during Amgen's Q3 2025 earnings call scheduled for November 4, 2025 [1]